HOME >> MEDICINE >> NEWS
Researchers find better way to predict childhood brain tumor outcomes

(Boston, MA) A distinctive "signature" of genes turned on and off greatly improves predictions of who has the best chance of survival of the most common type of childhood malignant brain tumor, according to a new study by researchers at Childrens Hospital Boston and their colleagues. If verified by other studies over the next several years, the gene expression profile may help children survive the malignant brain tumor with fewer serious side effects. The study also shows that medulloblastoma has key molecular differences from other brain tumors, which eventually may help researchers find more targeted treatment. The study is published in the Jan. 24 issue of the weekly journal Nature.

"Over the past 20 years, survival from medulloblastomas has dramatically improved," says pediatric neurologist Scott Pomeroy, first author of the paper. "In modern clinical trials, more than 80 percent of good-risk patients survive. Nearly 100 percent of the survivors, however, have learning disabilities, most have hearing loss and cataracts, and the majority are unable to live independent of their families as adults. A major goal of current treatment trials, then, is to reduce the level of radiation to lessen toxicity without compromising survival in good-risk patients."

Now, risk is defined by clinical criteria, such as the presence of metastases on MRI scanning, excessive tumor remaining in the brain after surgery, and examination of tumor tissue under a microscope. "Our predictor is much more accurate than these clinical criteria," says Pomeroy, also an associate professor at Harvard Medical School.

About 2,000 children a year are diagnosed with medulloblastoma, with diagnosis verified at the time of surgery. For this study, researchers examined gene expression patterns from 99 patient tumor samples of three different types of brain tumors. In addition to distinguishing tumor types from each other, the study found strong expression of a signaling protei
'"/>

Contact: Bess Andrews
elizabeth.andrews@TCH.Harvard.edu
617-355-6420
Harvard Medical School
24-Jan-2002


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
(Date:7/25/2014)... Hills, CA (PRWEB) July 25, 2014 Agoura ... a special promotion on Zoom Whitening. Zoom Whitening is one ... is only available through a dental professional. This light-assisted treatment ... into the structure of the tooth to break up stains ... is effective on coffee, tea, wine, soft drink and tobacco ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The rising pharmaceutical ... leading to the growth of the US PBM industry. A ... and value of pharmaceutical sales in the US over the ... be attributed to rise in the prescription volume over the ... Pharmacy Benefit Management (PBM): 2013 Edition” the demand for the ...
(Date:7/25/2014)... July 25, 2014 Ross A. Clevens, ... been invited to join the exclusive Obagi Clinical Advisory ... facial plastic surgeons, plastic surgeons and dermatologists. , ... exclusive Advisory Board of thought leaders held its first ... meeting was to give Obagi the opportunity to meet ...
(Date:7/25/2014)... (HealthDay News) -- Dietary changes can dramatically alter the ... basis, according to a new study. These ... detect and ease flare-ups for people with certain chronic ... Crohn,s disease), the researchers said. Trillions of bacteria ... human health isn,t well understood, the Massachusetts Institute of ...
(Date:7/25/2014)... July 25, 2014 ZeptoMetrix™ Corporation ... reliable and trusted products and services for infectious ... release of NATtrol™ RP Multimarker Controls - ... in vitro diagnostic, CE marked, unassayed external run ... assays the NATtrol™ RP Multimarker Controls - MDZ001 ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 2Health News:US Pharmacy Benefit Management (PBM) Market Trends and Developments Now Available at MarketReportsOnline.com 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2Health News:Diet Changes Can Alter Gut Bacteria, Study Says 2Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
(Date:7/24/2014)... 2014 Amgen (NASDAQ: AMGN ) today ... on Tuesday, July 29, 2014, after the close of the ... conference call with the investment community at 2 p.m. PT. ... A. Bradway , chairman and chief executive officer, and other ... of the conference call will be simultaneously broadcast over the ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... "the company") announced today that the company,s board of directors ... 31 to June 30. Accordingly, DelMar will file a Transition ... Jeffrey Bacha , president and CEO of DelMar stated, ... in achieving our goal of obtaining a senior exchange listing ...
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Second Quarter Financial Results 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
Cached News: